Advertisement
Canada markets open in 1 hour 8 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7311
    +0.0013 (+0.18%)
     
  • CRUDE OIL

    83.18
    +0.37 (+0.45%)
     
  • Bitcoin CAD

    87,637.80
    -3,581.37 (-3.93%)
     
  • CMC Crypto 200

    1,355.81
    -26.77 (-1.94%)
     
  • GOLD FUTURES

    2,339.80
    +1.40 (+0.06%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,466.25
    -198.25 (-1.12%)
     
  • VOLATILITY

    16.31
    +0.34 (+2.13%)
     
  • FTSE

    8,098.63
    +58.25 (+0.72%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter. Vertex’s Orkambi, Kalydeco, and Symdeko are top drugs in the cystic fibrosis market. Vertex stock’s 52-week low is $136.50, which it reached on December 7, 2017.